| [Fire Fighting] Containers can build up pressure if exposed to heat and/or fire. In case of fire use water spray, dry chemical, carbon dioxide, or chemical foam. | |
| [Ingestion] Get medical aid. Wash mouth out with water. | |
| [Inhalation] Remove from exposure to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. | |
| [Skin] Get medical aid. Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes. | |
| [Eyes] Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid. | |
| [Storage] Store in a cool, dry place. Store in a tightly closed container. | |
| [Handling] Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes. | |
| [Inhalation] May cause respiratory tract irritation. | |
| [Skin] May cause skin irritation. | |
| [Eyes] May cause eye irritation. | |
| [Ingestion] Harmful if swallowed. | |
| [EC Risk Phrase] R 22 | |
| [EC Safety Phrase] S 22 36/37 | |
| [Personal Protection] Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166. Skin: Wear appropriate protective gloves to prevent skin exposure. Clothing: Wear appropriate protective clothing to prevent skin exposure. | |
| [Respirators] Follow the OSHA respirator regulations found in 29CFR 1910.134 or European Standard EN 149. Always use a NIOSH or European Standard EN 149 approved respirator when necessary. | |
| [Exposure Effects] Headaches, dizziness, lightheadedness, disorientation, irritability, unresponsiveness, lethargy, stupor, weakness, paralysis, areflexia, syncope coma, and seizures may follow gastrointestinal symptoms. Chronic consumption of plants containing high concentrations of cyanogenic glycosides has been associated with polyneuropathy which include optic atrophy, nerve deafness, spastic paraparesis, ataxia, clonus and peripheral neuropathy. | |
| [Appearance] Odorless, white powder. | |
| [Solubility in water] 83 g/L | |
| [Melting Point] 226 | |
| [Usage] Studied extensively as a potential anti-cancer drug. Sold as a dietary supplement although no anti-cancer activity has been identified. | |
| [Product Name] (R)-Laenitrile | |
| [Synonyms] (R)-alpha-((6-o-beta-D-Glucopyranosyl-beta-D-glucopyranosyl)oxy)benzeneacetonitrile Amygdalin Amygdaloside Mandelonitrile beta-gentiobioside R-Amygdalin Vitamin B-17 | |
| [CAS] "CASEN_29883-15-6.htm">29883-15-6 | |
| [Formula] C20H27NO11 | |
| [Molecular Weight] 457.43 | |
| [EINECS] 249-925-3 | |
| [RTECS] OO8450000 | |
| [RTECS Class] Drug; Mutagen; Reproductive Effector; Human Data | |
| [Merck] 13,701 | |
| [Beilstein/Gmelin] 66856 | |
| [Beilstein Reference] 5-17-08-00118 | |
| [Small spills/leaks] Vacuum or sweep up material and place into a suitable disposal container. | |
| [Stability] No data. | |
| [Incompatibilities] Strong oxidizing agents, strong acids, strong bases. | |
| [Decomposition] Nitrogen oxides, carbon monoxide, carbon dioxide. |
Print